| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical compan...
 
																	Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company de...
 
																	
 
																	
 
																	
 
																	HC Wainwright & Co. analyst Matthew Keller reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $31 p...
 
																	The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on Acurx's Pediatric Investigati...
 
																	 
																	HC Wainwright & Co. analyst Matthew Keller maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and raises the price...